Web Results

Miglustat

en.wikipedia.org/wiki/Miglustat

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I ...

Miglustat for treatment of Niemann-Pick C disease: a randomised ...

www.ncbi.nlm.nih.gov/pubmed/17689147

Lancet Neurol. 2007 Sep;6(9):765-72. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Patterson MC(1), Vecchio D, Prady H, ...

Miglustat: MedlinePlus Drug Information

medlineplus.gov/druginfo/meds/a604015.html

Apr 15, 2016 ... Miglustat is used to treat Gaucher's disease (a condition in which a certain fatty substance is not broken down normally in the body and instead ...

DrugBank: Miglustat

www.drugbank.ca/drugs/DB00419

Jun 13, 2005 ... Miglustat is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of ...

Zavesca (miglustat

www.zavesca.com/

Zavesca (miglustat) Uses, Dosage, Side Effects - Drugs.com

www.drugs.com/zavesca.html

Zavesca (miglustat) reduces the formation of a certain protein in the body in people with type 1 Gaucher disease. Gaucher disease is a genetic condition in ...

European Medicines Agency - Find medicine - Zavesca

www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000435/human_med_001171.jsp&mid=WC0b01ac058001d124

Home · Find medicine; Human medicines. Zavesca. miglustat. Email; Print; Help. Share. About; Authorisation details; Product information; Assessment history ...

Zavesca, INN- Miglustat - European Medicines Agency - Europa.eu

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000435/WC500046726.pdf

Each capsule contains 100 mg miglustat. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM. Hard capsule. White capsules with “OGT ...

Zavesca, INN- Miglustat - European Medicines Agency

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000435/WC500046721.pdf

Miglustat reduces the biosynthesis of glucosylceramide from ceramide through the inhibition of the enzyme glucosylceramide synthase. Glucosylceramide is the  ...

Zavesca (miglustat) 100 mg hard capsules - Summary of Product ...

www.medicines.org.uk/emc/medicine/13933

Oct 20, 2015 ... Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SPC) by Actelion Pharmaceuticals UK Ltd.

More Info

Zavesca (Miglustat): Side Effects, Interactions, Warning, Dosage ...

www.rxlist.com

Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first ...

Zavesca - Actelion

www1.actelion.com

The usual dose of Zavesca® in adult NP-C patients was 200 mg miglustat three times a day, and was adjusted according to body surface area in pediatric NP-C ...

Miglustat: Indications, Side Effects, Warnings - Drugs.com

www.drugs.com

Easy to read patient leaflet for miglustat. Includes indications, proper use, special instructions, precautions, and possible side effects.